Company registration number 03120490 (England and Wales)
MAURIPHARM LIMITED
ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2025
PAGES FOR FILING WITH REGISTRAR
MAURIPHARM LIMITED
COMPANY INFORMATION
Director
Mr A C Kureeman
Company number
03120490
Registered office
224 Barnett Wood Lane
Ashstead
Surrey
England
KT21 2DB
Accountants
Xeinadin
First Floor Secure House
Lulworth Close
Chandler's Ford
Eastleigh
Hampshire
England
SO53 3TL
MAURIPHARM LIMITED
CONTENTS
Page
Director's report
1
Accountants' report
2
Balance sheet
3
Notes to the financial statements
4 - 7
MAURIPHARM LIMITED
DIRECTOR'S REPORT
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 1 -

The director presents his annual report and financial statements for the year ended 30 November 2025.

Director

The director who held office during the year and up to the date of signature of the financial statements was as follows:

Mr A C Kureeman
Small companies exemption

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

On behalf of the board
Mr A C Kureeman
Director
10 August 2026
MAURIPHARM LIMITED
ACCOUNTANTS' REPORT TO THE DIRECTOR ON THE PREPARATION OF THE UNAUDITED STATUTORY FINANCIAL STATEMENTS OF MAURIPHARM LIMITED FOR THE YEAR ENDED 30 NOVEMBER 2025
- 2 -

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the financial statements of Mauripharm Limited for the year ended 30 November 2025 which comprise, the balance sheet and the related notes from the company’s accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at https://www.icaew.com/regulation.

This report is made solely to the b oard of d irectors of Mauripharm Limited, as a body, in accordance with the terms of our engagement letter. Our work has been undertaken solely to prepare for your approval the financial statements of Mauripharm Limited and state those matters that we have agreed to state to the b oard of d irectors of Mauripharm Limited, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Mauripharm Limited and its b oard of d irectors as a body, for our work or for this report.

It is your duty to ensure that Mauripharm Limited has kept adequate accounting records and to prepare statutory financial statements that give a true and fair view of the assets, liabilities, financial position and profit of Mauripharm Limited. You consider that Mauripharm Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the financial statements of Mauripharm Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory f inancial statements.

Xeinadin
First Floor Secure House
Lulworth Close
Chandler's Ford
Eastleigh
Hampshire
SO53 3TL
England
10 August 2026
MAURIPHARM LIMITED
BALANCE SHEET
AS AT 30 NOVEMBER 2025
30 November 2025
- 3 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
4
14,503
5,364
Current assets
Stocks
128,905
140,419
Debtors
5
1,334,649
1,136,819
Cash at bank and in hand
177,113
372,778
1,640,667
1,650,016
Creditors: amounts falling due within one year
6
(443,399)
(393,279)
Net current assets
1,197,268
1,256,737
Total assets less current liabilities
1,211,771
1,262,101
Creditors: amounts falling due after more than one year
7
(138,056)
(164,722)
Net assets
1,073,715
1,097,379
Capital and reserves
Called up share capital
200
200
Profit and loss reserves
1,073,515
1,097,179
Total equity
1,073,715
1,097,379

For the financial year ended 30 November 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

T he member has not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved and signed by the director and authorised for issue on 10 August 2026
Mr A C Kureeman
Director
Company registration number 03120490 (England and Wales)
MAURIPHARM LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 4 -
1
Accounting policies
Company information

Mauripharm Limited is a private company limited by shares incorporated in England and Wales. The registered office is 224 Barnett Wood Lane, Ashstead, Surrey, England, KT21 2DB.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2
Turnover

Revenue comprises sales of goods or services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts. Revenue is recognised when performance obligations are satisfied and the control of goods or services is transferred to the buyer. Where the performance obligation is satisfied over time, revenue is recognised in accordance with its progress towards complete satisfaction of that performance obligation.

When cash inflows are deferred and represent a financing arrangement, the promised consideration is adjusted for the effects of the time value of money, which is recognised as interest income.

The nature, timing of satisfaction of performance obligations and significant payment terms of the company's major sources of revenue are as follows:

1.3
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is twenty years.

For the purposes of impairment testing, goodwill is allocated to the cash-generating units expected to benefit from the acquisition. Cash-generating units to which goodwill has been allocated are tested for impairment at least annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

MAURIPHARM LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
1
Accounting policies
(Continued)
- 5 -

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures and fittings
20% on reducing balance
Computers
25% on cost
Motor vehicles
Enter depreciation rate via StatDB - cd78
1.5
Stocks

Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

1.6
Financial instruments

The company enters into basic financial instruments, which result in the recognition of financial assets and liabilities. Financial instruments are recognised at amortised cost. At the end of each reporting period, financial instruments are assessed for evidence of impairment and changes are recognised in the Statement of Income and Retained Earnings.

1.7
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.8
Retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

MAURIPHARM LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
1
Accounting policies
(Continued)
- 6 -
1.9
Leases
As lessee

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.

Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the balance sheet as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to profit or loss so as to produce a constant periodic rate of interest on the remaining balance of the liability.

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the lease s asset are consumed.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
18
18
3
Intangible fixed assets
Goodwill
£
Cost
At 1 December 2024 and 30 November 2025
136,000
Amortisation and impairment
At 1 December 2024 and 30 November 2025
136,000
Carrying amount
At 30 November 2025
-
0
At 30 November 2024
-
0
MAURIPHARM LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 NOVEMBER 2025
- 7 -
4
Tangible fixed assets
Fixtures and fittings
Computers
Motor vehicles
Total
£
£
£
£
Cost
At 1 December 2024
117,939
16,477
-
0
134,416
Additions
-
0
-
0
12,255
12,255
At 30 November 2025
117,939
16,477
12,255
146,671
Depreciation and impairment
At 1 December 2024
112,575
16,477
-
0
129,052
Depreciation charged in the year
1,073
-
0
2,043
3,116
At 30 November 2025
113,648
16,477
2,043
132,168
Carrying amount
At 30 November 2025
4,291
-
0
10,212
14,503
At 30 November 2024
5,364
-
0
-
0
5,364
5
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
334,045
339,133
Other debtors
1,000,604
797,686
1,334,649
1,136,819
6
Creditors: amounts falling due within one year
2025
2024
£
£
Bank loans
26,667
26,667
Trade creditors
360,712
351,389
Taxation and social security
32,466
11,766
Other creditors
23,554
3,457
443,399
393,279
7
Creditors: amounts falling due after more than one year
2025
2024
£
£
Bank loans and overdrafts
138,056
164,722
2025-11-30 2024-12-01 false false false 10 August 2026 CCH Software CCH Accounts Production 2026.100 No description of principal activity Mr A C Kureeman 03120490 2024-12-01 2025-11-30 03120490 bus:Director1 2024-12-01 2025-11-30 03120490 bus:RegisteredOffice 2024-12-01 2025-11-30 03120490 2025-11-30 03120490 2024-11-30 03120490 core:FurnitureFittings 2025-11-30 03120490 core:ComputerEquipment 2025-11-30 03120490 core:MotorVehicles 2025-11-30 03120490 core:FurnitureFittings 2024-11-30 03120490 core:ComputerEquipment 2024-11-30 03120490 core:MotorVehicles 2024-11-30 03120490 core:CurrentFinancialInstruments core:WithinOneYear 2025-11-30 03120490 core:CurrentFinancialInstruments core:WithinOneYear 2024-11-30 03120490 core:WithinOneYear 2025-11-30 03120490 core:WithinOneYear 2024-11-30 03120490 core:AfterOneYear 2025-11-30 03120490 core:AfterOneYear 2024-11-30 03120490 core:CurrentFinancialInstruments 2025-11-30 03120490 core:CurrentFinancialInstruments 2024-11-30 03120490 core:ShareCapital 2025-11-30 03120490 core:ShareCapital 2024-11-30 03120490 core:RetainedEarningsAccumulatedLosses 2025-11-30 03120490 core:RetainedEarningsAccumulatedLosses 2024-11-30 03120490 core:Goodwill 2024-12-01 2025-11-30 03120490 core:FurnitureFittings 2024-12-01 2025-11-30 03120490 core:ComputerEquipment 2024-12-01 2025-11-30 03120490 core:MotorVehicles 2024-12-01 2025-11-30 03120490 2023-12-01 2024-11-30 03120490 core:Goodwill 2024-11-30 03120490 core:Goodwill 2025-11-30 03120490 core:Goodwill 2024-11-30 03120490 core:FurnitureFittings 2024-11-30 03120490 core:ComputerEquipment 2024-11-30 03120490 core:MotorVehicles 2024-11-30 03120490 2024-11-30 03120490 core:Non-currentFinancialInstruments 2025-11-30 03120490 core:Non-currentFinancialInstruments 2024-11-30 03120490 bus:PrivateLimitedCompanyLtd 2024-12-01 2025-11-30 03120490 bus:SmallCompaniesRegimeForAccounts 2024-12-01 2025-11-30 03120490 bus:FRS102 2024-12-01 2025-11-30 03120490 bus:AuditExemptWithAccountantsReport 2024-12-01 2025-11-30 03120490 bus:FullAccounts 2024-12-01 2025-11-30 xbrli:pure xbrli:shares iso4217:GBP